68ga-dotanoc
Small moleculeexperimental
Clinical trial activity
9 trials · 8 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
3
Phase 4
0
Earliest trial started Nov 1, 2012 (NCT01747096)
Timeline
Indications
Mechanism of action
- Unspecified targetRadiopharmaceutical
radiopharmaceutical
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 68-ga-dotanoc
- 68ga-dotanoc
- dotanoc
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05268952 | N/A | May 27, 2019 | University of Antwerp |
| NCT05255133 | N/A | Oct 9, 2017 | Kom Op Tegen Kanker, University of Antwerp |
| NCT02840149 | Phase 3 | Jan 1, 2017 | McGill University |
| NCT02967666 | Phase 1 | Nov 1, 2016 | National University of Singapore |
| NCT02845570 | Phase 1 | Jul 31, 2016 | Nanyang Technological University, National University of Singapore |
| NCT02824419 | Phase 2/Phase 3 (Phase 3) | May 1, 2016 | University of Turku |
| NCT02608203 | Phase 2/Phase 3 (Phase 3) | Dec 1, 2015 | Aix-University of Marseille |
| NCT02389101 | N/A | Oct 31, 2014 | University of Turku |
| NCT01747096 | N/A | Nov 1, 2012 | University of Nantes |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (8)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National University of Singapore | Academic/Hospital | 2 | 2 | 1 | 2016 |
| University of Antwerp | Academic/Hospital | 2 | 2 | 1 | 2017 |
| University of Turku | Academic/Hospital | 2 | 2 | 2 | 2014 |
| Aix-University of Marseille | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Kom Op Tegen Kanker | Academic/Hospital | 1 | 0 | 1 | 2017 |
| McGill University | Academic/Hospital | 1 | 1 | 1 | 2017 |
| Nanyang Technological University | Academic/Hospital | 1 | 0 | 1 | 2016 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2012 |
8 organizations
Page 1 / 1